Interleukin-6 and airflow limitation in chemical warfare patients with chronic obstructive pulmonary disease
Davood Attaran1, Shahrzad M Lari1, Mohammad Towhidi1, Hassan Ghobadi Marallu2, Hossein Ayatollahi1, Mohammad Khajehdaluee1, Mostafa Ghanei3, Reza Basiri1
1Lung Disease and Tuberculosis Research Center, Mashhad University of Medical Science, 2Ardabil University of Medical Sciences, 3Research Center of Chemical Injuries, Baqiyatallah University of Medical Sciences, Tehran, Iran
Objectives: Chronic obstructive pulmonary disease (COPD) is one of the main late complications of sulfur mustard poisoning. The aim of this study was to evaluate serum levels of interleukin (IL)-6 in war veterans with pulmonary complications of sulfur mustard poisoning and their correlation with severity of airways disease.
Methods: Fifty consecutive patients with sulfur mustard poisoning and stable COPD, and of mean age 46.3 ± 9.18 years were enrolled in this study. Thirty healthy men were selected as controls and matched to cases by age and body mass index. Spirometry, arterial blood gas, six-minute walk test, BODE (body mass index, obstruction, dyspnea, and exercise capacity), and St George’s Respiratory Questionnaire about quality of life were evaluated. Serum IL-6 was measured in both patient and control groups.
Results: Fifty-four percent of patients had moderate COPD. Mean serum IL-6 levels were 15.01 ± standard deviation (SD) 0.61 pg/dL and 4.59 ± 3.40 pg/dL in the case and control groups, respectively (P = 0.03). There was a significant correlation between IL-6 levels and Global Initiative for Chronic Obstructive Lung Disease stage (r = 0.25, P = 0.04) and between IL-6 and BODE index (r = 0.38, P = 0.01). There was also a significant negative correlation between serum IL-6 and forced expiratory volume in one second (FEV1, r = -0.36, P = 0.016).
Conclusion: Our findings suggest that serum IL-6 is increased in patients with sulfur mustard poisoning and COPD, and may have a direct association with airflow limitation.
Keywords: sulfur mustard, chronic obstructive pulmonary disease, interleukin-6, inflammation, chemical warfare
This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php
Readers of this article also read:
Product wastage from modern human growth hormone administration devices: a laboratory and computer simulation analysis
Pollock RF, Qian Y, Wisniewski T, Seitz L, Kappelgaard AM
Published Date: 1 August 2013
Khan MA, López-Muñoz MM, Kaspar CW, Hung KF
Published Date: 4 April 2013
Li C, Wang Y, Zhang X, Deng L, Zhang Y, Chen Z
Published Date: 12 March 2013
Xirou T, Theodossiadis PG, Apostolopoulos M, Kabanarou SA, Feretis E, Ladas ID, Koutsandrea C
Published Date: 20 July 2012
Chauhan A, Zubair S, Tufail S, Sherwani A, Sajid M, Raman SC, Azam A, Owais M
Published Date: 12 October 2011
Usefulness of serum mass spectrometry to identify women diagnosed with higher grades of cervical intraepithelial neoplasia may differ by race
Matthews R, Azuero A, Asmellash S, Brewster E, Partridge EE, Piyathilake CJ
Published Date: 12 July 2011
Nourani MR, Ebrahimi M, Roudkenar MH, Vahedi E, Ghanei M, Imani Fooladi AA
Published Date: 26 May 2011
Clinical effectiveness of the Respimat® inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices
Felix SF Ram, Celso R Carvallho, et al
Published Date: 2 February 2011
A Catherine Simpson, Joanne Young, Margaret Donahue, et al
Published Date: 10 May 2010
Jonette Keri, Michael Shiman
Published Date: 17 June 2009